Paris, France, 20 November 2020: Rexgenero-France (previously aratinga.bio), a preclinical stage biotech company developing an off-the-shelf and universal chimeric antigen receptor (CAR)-T therapy which allows in vivo targeting and transduction of T-cells, today announces the presentation of a novel approach for quantitative real-time particle analysis of lentivirus vectors at the Antibody Industrial Symposium 2020 on Monday 23 November 2020 at 18:00 CET.
The study was conducted in collaboration with Myriade to explore new processes to measure lentiviral vector physical titre for: (1) characterization of lentiviral products for use in CAR-T cell products following purification and concentration; and (2) in-process controls during upstream and downstream processing.
Using Myriade’s Videodrop (Interferometry Light Microscopy), a new type of equipment that measures the concentration of nanoparticles from a single drop of sample, the research team achieved results consistent with the standard lentiviral vector physical titration methods (ELISA p24 protein quantification and Tunable Resistive Pulse Sensing).
“Accurate measurements of lentiviral vector physical titres are crucial, as the titre largely determines transduction efficiency and the number of integrated gene copies in the target cell. Developing reliable and efficient methods for measuring lentiviral vector physical titres is integral to production of our CAR-T cell components and the development of rigorous in-process controls,” commented, Dr. Cecile Bauche, Vice President and Chief Scientific Officer at Rexgenero. “We are excited to present data collected using Myriade’s Videodrop at AIS 2020. Compared to the standard lentiviral vector physical titration processes, this novel approach is real-time, label-free and filtration-free, and could overcome challenges faced using the traditional methods. We look forward to further work with the Myriade team.”
Details of the poster presentation are as follows:
Event: Antibody Industrial Symposium 2020
Title: Novel approach for quantitative real-time particle analysis of lentiviral vectors
Date: 23 November 2020
Time: 18:00 PM-19:00 PM (CET)
Session: Poster Session
Presenters: Cécile Bauche (Rexgenero France) / Marie Berger & Matthieu Greffet (Myriade)
Conference link: https://aiscongress.com/
Videodrop films in real time all particles between 10 nm and 10 µm in a drop. No labelling is needed, and the process is real-time, label-free, filtration-free, non-destructive and only requires 5–10 μL sample volume.
Rexgenero is a privately held, UK-based cell and gene therapy company pioneering the development of therapies to treat serious diseases such as chronic limb-threatening ischaemia (CLI), cancer and immunological disorders.
Rexgenero’s lead product, REX-001, consists of a suspension of immune and progenitor cells involved in immune modulation, blood vessel regeneration and remodelling and improvement in blood flow. It is manufactured using a patient’s own cells, avoiding undesired immune responses. REX-001 is currently being tested in pivotal, placebo-controlled, double-blind, adaptive Phase III SALAMANDER trials in patients with CLI and diabetes mellitus at multiple sites across Europe. Previous randomised REX-001 clinical trials have already demonstrated statistically significant proof of concept. In a Phase I/II and Phase II clinical trial, REX-001 showed very strong positive results in improvement of blood flow, healing of ulcers and alleviating chronic ischemic rest pain. All ulcers healed within 12 months in 82% of patients after treatment with REX-001 at the dose being currently tested in Phase III trials.
The company also has a pioneering synthetic gene delivery platform, including an off-the-shelf CAR-T therapy allowing the in vivo targeting and transduction of T-cells.
Rexgenero’s lentivector, encoding for the Chimeric Antigen Receptor, is coated with a polymeric envelope grafted with an anti-CD3 targeting moiety to target T-cells. In contrast to approved ex vivo CAR T-cell therapies, the company’s in vivo technology requires low-cost manufacturing. The genetic modification to express the CAR is generated directly in the patient. Rexgenero’s inducible, switchable, in vivo CAR-T platform, represents a significant advantage over current recently approved ex vivo CAR-T therapies, with the potential for more effective, more universal, and safer treatments.
Rexgenero has offices in London, UK with R&D and manufacturing operations in Seville, Spain and Paris, France and additional manufacturing capability in Frankfurt, Germany.
For more information, please visit www.rexgenero.com
Connect with us: Twitter: @_Rexgenero; LinkedIn: https://www.linkedin.com/company/rexgenero-limited/